June 18, 2025 08:51 AM EDTUpdated 01:43 PM
Editor's note
China

Watch Post-Hoc Live: Chi­na is still the top con­ver­sa­tion starter at BIO

Jaimy Lee

Deputy Editor

To­day on Post-Hoc Live, we’re bring­ing you in­ter­views live from Boston, where sev­er­al of our re­porters have spent the last few days cov­er­ing BIO’s an­nu­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

Grail shares jump on study re­sults for can­cer test

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

Schol­ar Rock’s mus­cle-pre­serv­ing obe­si­ty drug add-on looks com­pet­i­tive

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times